Fosaprepitant Dimeglumine Injection shortage
Fosaprepitant Dimeglumine Injection is currently listed in shortage by the FDA. The FDA lists 1 affected product. This page was last refreshed from FDA data on Sep 22, 2026.
Fresenius Kabi is stopping its fosaprepitant dimeglumine injection, and this change may be permanent. The same medicine is still listed by other manufacturers, including as Emend (fosaprepitant dimeglumine) injection.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Fosaprepitant Dimeglumine Injection. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Apr 8, 2026Currently in shortage1 of 1 product affected.
-
Apr 8, 2026First reported to the FDA1 product first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Fresenius Kabi USA, LLC 📞 888-386-1300 1 NDC click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Fosaprepitant Dimeglumine, Injection, 150 mg/5 mL (NDC 63323-972-10) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Fosaprepitant Dimeglumine Injection — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Fosaprepitant Dimeglumine Injection? options further down this page.
Why is Fosaprepitant Dimeglumine Injection in shortage?
Fresenius Kabi USA has decided to permanently stop making their version of fosaprepitant dimeglumine injection — specifically the 150 mg/5 mL vial (NDC 63323-972-10). That's the reason this product shows up on the FDA shortage list.
It's worth knowing that Fresenius Kabi didn't share a more detailed public explanation for why they made this decision — just that manufacturing of this particular product is being discontinued. This report only covers Fresenius Kabi's product, so it doesn't speak to what other manufacturers may or may not have available.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Fosaprepitant Dimeglumine Injection, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Fosaprepitant Dimeglumine Injection?
Fosaprepitant dimeglumine injection is currently on the FDA drug-shortage list. This is the medicine often given with chemotherapy to help prevent nausea and vomiting, so I want to walk you through what the report shows.
The report covers the one strength, 150 mg/5 mL, and right now that strength has no available source from the manufacturer on this record. The reason given is that Fresenius Kabi is discontinuing the manufacture of this product. Because this is a planned discontinuation rather than a temporary delay, this particular supply may not return. That said, this report reflects only one manufacturer — several other companies make the same medicine, so it is not gone from the market as a whole.
Here is what I suggest, in order:
- Do not stop, skip, or change how you receive this medicine on your own — talk with your care team first.
- Since the same medicine (fosaprepitant dimeglumine, 150 mg/5 mL and similar) is made by other makers such as Merck, Hikma, Baxter, Dr. Reddy's, and others, your pharmacy may be able to source one of these, though it may not be in local stock right away.
- Because this product is being discontinued, ask your prescriber or pharmacist about a clinician-chosen option.
Manufacturer contact numbers are listed on this page for reference; pharmacies usually handle those calls. This is national, manufacturer-reported data and may not match your local pharmacy's actual stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Fosaprepitant Dimeglumine Injection?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Fosaprepitant Dimeglumine Injection is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Emend | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Injection, Powder, Lyophilized, For Solution · Intravenous | Merck Sharp & Dohme LLC | 00006-3061-00 |
| Fosaprepitant Dimeglumine | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Injection, Powder, Lyophilized, For Solution · Intravenous | Hikma Pharmaceuticals USA Inc. | 00143-9384-01 |
| Fosaprepitant | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Injection, Powder, Lyophilized, For Solution · Intravenous | Baxter Healthcare Corporation | 00338-0008-01 |
| Fosaprepitant | FOSAPREPITANT DIMEGLUMINE 150 mg/1 | Injection, Powder, Lyophilized, For Solution · Intravenous | Actavis Pharma, Inc. | 00591-4385-79 |
| Fosaprepitant | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Injection, Powder, Lyophilized, For Solution · Intravenous | NorthStar RxLLC | 16714-0248-01 |
| Fosaprepitant | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Injection, Powder, Lyophilized, For Solution · Intravenous | Camber Pharmaceuticals, Inc. | 31722-0165-31 |
| Fosaprepitant | FOSAPREPITANT DIMEGLUMINE 150 mg/1 | Injection, Powder, Lyophilized, For Solution · Intravenous | Dr. Reddy's Laboratories Inc., | 43598-0671-11 |
| Fosaprepitant | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Injection, Powder, Lyophilized, For Solution · Intravenous | Dr. Reddy's Laboratories Inc., | 43598-0859-11 |
| Fosaprepitant Dimeglumine | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Injection, Powder, Lyophilized, For Solution · Intravenous | Eugia US LLC | 55150-0299-01 |
| Fosaprepitant | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Injection, Powder, Lyophilized, For Solution · Intravenous | Mylan Institutional LLC | 67457-0889-10 |
| Fosaprepitant | FOSAPREPITANT DIMEGLUMINE 150 mg/5mL | Injection, Powder, Lyophilized, For Solution · Intravenous | BluePoint Laboratories | 68001-0421-22 |
| Focinvez | FOSAPREPITANT DIMEGLUMINE 150 mg/50mL | Injection · Intravenous | Amneal Pharmaceuticals LLC | 70121-2631-01 |
Therapeutic equivalents & pricing 25 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Emend 150 mg/5mL | Merck | 1 vial | — | AP | FDA listed |
| Fosaprepitant Dimeglumine 150 mg/5mL | Hikma | 1 vial | — | AP | FDA listed |
| Fosaprepitant Dimeglumine 150 mg/5mL | Hikma | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | Baxter | 1 vial | — | — | FDA listed |
| Fosaprepitant 150 mg | Actavis | 1 injection | — | — | FDA listed |
| Fosaprepitant 150 mg/5mL | NorthStar | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | Camber | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg | Dr. | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | Dr. | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | Dr. | 1 vial | — | AP | FDA listed |
| Fosaprepitant Dimeglumine 150 mg/5mL | Eugia | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | Fresenius | 1 vial | — | AP | FDA listed |
| Fosaprepitant Dimeglumine 150 mg/5mL | Qilu | 1 vial | — | AP | FDA listed |
| fosaprepitant 150 mg/5mL | Mylan | 1 vial | — | — | FDA listed |
| Fosaprepitant 150 mg/5mL | BluePoint | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | BluePoint | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | Chia | 1 vial | — | AP | FDA listed |
| fosaprepitant 150 mg/5mL | BE | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | Bryant | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | Novadoz | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | Novadoz | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | Northstar | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | Avenacy, | 1 vial | — | AP | FDA listed |
| Fosaprepitant 150 mg/5mL | BluePoint | 1 vial | — | — | Discontinued |
| Navitrux 150 mg/5mL | AVYXA | 1 vial | — | — | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Fosaprepitant Dimeglumine Injection — that fall in the same broad treatment class (antiemetic/antivertigo agents) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other gastroenterology shortages
Fosaprepitant Dimeglumine Injection shortage FAQs
Is Fosaprepitant Dimeglumine Injection in shortage?
Which products are affected?
When will Fosaprepitant Dimeglumine Injection be available again?
Can I still get Fosaprepitant Dimeglumine somewhere?
What should I do if I take Fosaprepitant Dimeglumine Injection?
Still have a question about the Fosaprepitant Dimeglumine Injection shortage?
Ask a pharmacist about this shortage →View Fosaprepitant Dimeglumine Injection on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.